Cadrenal Therapeutics, Inc.

NasdaqCM:CVKD Stock Report

Market Cap: US$29.3m

Cadrenal Therapeutics Management

Management criteria checks 1/4

Cadrenal Therapeutics' CEO is Quang Pham, appointed in Jan 2022, has a tenure of 2.92 years. total yearly compensation is $967.00K, comprised of 68.5% salary and 31.5% bonuses, including company stock and options. directly owns 23.47% of the company’s shares, worth $6.88M. The average tenure of the management team and the board of directors is 2.5 years and 1.9 years respectively.

Key information

Quang Pham

Chief executive officer

US$967.0k

Total compensation

CEO salary percentage68.5%
CEO tenure2.9yrs
CEO ownership23.5%
Management average tenure2.5yrs
Board average tenure1.9yrs

Recent management updates

Recent updates

Here's Why We're Watching Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Situation

Oct 31
Here's Why We're Watching Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Situation

Cadrenal Therapeutics (NASDAQ:CVKD) Is In A Good Position To Deliver On Growth Plans

Jan 30
Cadrenal Therapeutics (NASDAQ:CVKD) Is In A Good Position To Deliver On Growth Plans

CEO Compensation Analysis

How has Quang Pham's remuneration changed compared to Cadrenal Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$8m

Jun 30 2024n/an/a

-US$6m

Mar 31 2024n/an/a

-US$5m

Dec 31 2023US$967kUS$663k

-US$8m

Sep 30 2023n/an/a

-US$13m

Jun 30 2023n/an/a

-US$13m

Mar 31 2023n/an/a

-US$12m

Dec 31 2022US$822kUS$350k

-US$7m

Compensation vs Market: Quang's total compensation ($USD967.00K) is above average for companies of similar size in the US market ($USD650.40K).

Compensation vs Earnings: Quang's compensation has increased whilst the company is unprofitable.

CEO

Quang Pham (59 yo)

2.9yrs

Tenure

US$967,000

Compensation

Mr. Quang X. Pham Founded Lathian Health, Inc. (Formerly known as MyDrugRep, Inc.) in January 2000 and also serves as its Chief Executive Officer. He is a Director at Cognition Therapeutics, Inc. since Oct...

Leadership Team

NamePositionTenureCompensationOwnership
Quang Pham
Chairman & CEO2.9yrsUS$967.00k23.47%
$ 6.9m
Matthew Szot
Co-Founder & CFO2.6yrsUS$844.89k1.87%
$ 548.3k
Douglas Losordo
Chief Medical Officer2.3yrsUS$528.69k0%
$ 0
Jeffrey Cole
Chief Operating Officerless than a yearno datano data

2.5yrs

Average Tenure

59yo

Average Age

Experienced Management: CVKD's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Quang Pham
Chairman & CEOno dataUS$967.00k23.47%
$ 6.9m
Glynn Wilson
Independent Director1.9yrsUS$35.00k0.19%
$ 54.8k
Steven Zelenkofske
Independent Director1.9yrsUS$35.00k0.15%
$ 43.9k
C. Gibson
Member of Scientific Advisory Boardno datano datano data
John Murphy
Independent Director1.9yrsUS$50.00k2.3%
$ 674.2k
Robert Lisicki
Independent Director1.4yrsUS$74.50k0%
$ 0
Sean Pokorney
Member of Scientific Advisory Boardno datano datano data
Christopher Granger
Member of Scientific Advisory Boardno datano datano data
Elaine Hylek
Member of Scientific Advisory Boardno datano datano data
A. Lincoff
Member of Scientific Advisory Boardno datano datano data
Richard Whitlock
Member of Scientific Advisory Boardno datano datano data
Wolfgang Winkelmayer
Member of Scientific Advisory Boardno datano datano data

1.9yrs

Average Tenure

65yo

Average Age

Experienced Board: CVKD's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 02:16
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cadrenal Therapeutics, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joseph PantginisH.C. Wainwright & Co.
Robert LeBoyerNOBLE Capital Markets, Inc.
David BautzZacks Small-Cap Research